MSB

8.42%

$1.03 mesoblast limited

Ann: Trading Halt, page-264

First 264 Last

Share
Profile

Follow
Harymeso

402 Posts.

16

20/11/19

15:42

Post #: 41534581
Share

Originally posted by otherperspective ↑

Harymeso.
I have been maintaining radio silence whilst I have been building up my own shareholding . I added my last 15,000 shares today. I was originally concerned that Capital might dump their remaining holding but I have been reassured that they have been bid for their remaining holding and have not responded to the opportunity to sell. I am also assured that there is no sign of further selling on the share register... but that is just hearsay.
Near term, I still read them as a potential seller but we are in a sort of “Mexican standoff” where the price is capped and buyer and sellers have reached a stalemate. I do not see this resolving itself until another price sensitive announcement swings the pendulum decisively one way or the other . I cannot believe I got the opportunity to sneak in and by a few hundred thousand at a big discount to the recent placing.

Re PAR I do not want to get drawn into a slanging match between threads. I note that two directors have just purchased a meaningful number of shares personally so they must be excited about their own prospects. They have secured a “use” patent for an old treatment therapy. I have not doubt that this works on low grade pain as it acts as a nerve growth inhibitor but I do not believe it improves function or restores/hydrated surrounding tissue. As there is no particular alternative out there right now they should do fine . When people understand what Mesoblast can do to treat the same condition, they will be even more impressed ...in my opinion of course. I should add that Mesoblast is unlikely to prioritise this treatment condition in the near future... the focus is currently on establishing the correct pricing formula for their other phase three therapies.
I will write a much longer piece shortly about Mesoblasts prospects. I think the Grunenthal deal has shown other major players what is possible ....put up a relatively modest up front now and reap the potential huge rewards of a successful phase three trial... and steal a match on all your competitors . I think the message will resonate and I would not be surprised if someone jumps the gun and pays a large upfront ( $150-200m?) in Cal Q1 before the trial results are known . Meanwhile I note that Bell Potter has speculated that the Company will want to refinance its debt following a successful fundraising . I also note that Edison Research have published a note in October which substantially upgraded the value of aGVHD compared to Bell Potters outlook.
I think that Mesoblast is getting ready to finish off the “data scrub” for its BLA application which should be lodged towards the end of December . By now they should have had final feedback from the FDA and I am very optimistic of a successful outcome. As a new therapy we should be prepared for the FDA to require an ADCOM meeting in the third month but that is not something to be concerned about should it happen. Got to rush . I am very excited about the months ahead. Please do your own research. GLA.

Expand

Thanks again otherperspective. A most valued insight. Pleased you secured a nice top up. AGM hopefully worth to effort to attend. Cheers

MSB Price at posting: $1.78 Sentiment: Buy Disclosure: Held
12 Upvote

0 Great analysis

Reply

Top Stories

CCO

The Calmer Co’s Anthony Noble reflects on record breaking FY24

PYC

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

VYS

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

HLX

Helix investor makes partial takeover bid, proposing board changes

TBN

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

CYM

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

HVN

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

LLC

Lendlease sells off US east coast construction operations in latest global divestment push

There are more pages in this discussion • 12 more messages in this thread...

First 264 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.03		Change 0.080(8.42%)		Mkt cap ! $1.176B

Open	High	Low	Value	Volume
95.5¢	$1.03	95.0¢	$43.38M	42.28M

Buyers (Bids)

No.	Vol.	Price($)
4	72752	$1.01

Sellers (Offers)

Price($)	Vol.	No.
$1.03	205100	2

View Market Depth

No.	Vol.	Price($)
1	20000	1.005
5	57985	1.000
1	50000	0.995
2	20525	0.990
1	10000	0.985

Price($)	Vol.	No.
1.035	190122	7
1.045	39714	5
1.050	21696	6
1.060	9750	2
1.065	5780	1

Last trade - 16.10pm 30/08/2024 (20 minute delay)

MSB (ASX) Chart

Ann: Trading Halt, page-264

The Calmer Co’s Anthony Noble reflects on record breaking FY24

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

Helix investor makes partial takeover bid, proposing board changes

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

Lendlease sells off US east coast construction operations in latest global divestment push

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Trading Halt, page-264

Top Stories

The Calmer Co’s Anthony Noble reflects on record breaking FY24

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

Helix investor makes partial takeover bid, proposing board changes

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

Lendlease sells off US east coast construction operations in latest global divestment push

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News